{{Rsnum
|rsid=6071980
|Chromosome=20
|position=40239936
|Orientation=plus
|GMAF=0.1648
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 2.7 | 27.4 | 69.9
| HCB | 4.4 | 40.9 | 54.7
| JPT | 3.5 | 44.2 | 52.2
| YRI | 2.0 | 19.7 | 78.2
| ASW | 5.3 | 15.8 | 78.9
| CHB | 4.4 | 40.9 | 54.7
| CHD | 5.5 | 38.5 | 56.0
| GIH | 4.0 | 36.6 | 59.4
| LWK | 0.9 | 21.8 | 77.3
| MEX | 3.4 | 27.6 | 69.0
| MKK | 3.2 | 25.6 | 71.2
| TSI | 2.9 | 31.4 | 65.7
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs6071980
|Name_s=
|Gene_s=-
|Feature=
|Evidence=PubMed ID:18615156
|Annotation=This variant is significantly associated with the efficacy of anti-TNF treatment in rheumatoid arthritis (Adjusted P-value: 0.000003; OR: 7.6 (1.9, 44.6)). The study is a genome-wide association study using the Illumina HapMap300 SNP chip on 89 RA patients prospectively followed after beginning of anti-TNF therapy.
|Drugs=adalimumab; etanercept; infliximab
|Drug Classes=
|Diseases=Arthritis, Rheumatoid
|Curation Level=Curated
|PharmGKB Accession ID=PA162928833
}}

{{PMID Auto
|PMID=20423481
|Title=Lack of replication of genetic predictors for the rheumatoid arthritis response to anti-TNF treatments: a prospective case-only study.
|OA=1
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs6071980
|overall_frequency_n=16
|overall_frequency_d=128
|overall_frequency=0.125
|n_genomes=15
|n_genomes_annotated=0
|n_haplomes=17
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}